Worth Asset Management’s AnaptysBio ANAB Stock Holding History

Worth Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$10K	–	456
2022 Q2	$10K	Buy	+500	New	+$11.1K	0.01%	343

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Worth Asset Management's ANAB Position: Q3 2022 in Review

Worth Asset Management sold out of AnaptysBio (ANAB) in Q3 2022, closing a stake of 500 shares — an estimated $10K sold.

Worth Asset Management first reported a position in ANAB in Q2 2022 and held it in 1 quarter. The position peaked at $10K in Q2 2022. 114 funds tracked by Wall St. Rank hold ANAB as of Q3 2022.

Worth Asset Management reported no remaining AnaptysBio position as of Q3 2022 after selling out during the quarter.
Worth Asset Management sold 500 AnaptysBio shares in Q3 2022, an estimated $10K.
Worth Asset Management first reported a position in AnaptysBio in Q2 2022 and held it in 1 quarter.
Worth Asset Management's AnaptysBio position peaked at $10K in Q2 2022.
114 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2022.

Based on Worth Asset Management's 13F filing for Q3 2022, filed 7 Oct 2022.